Evidence overview
Rhodiola
Rhodiola rosea (golden root) is one of the better-studied adaptogenic herbs, with a clinical literature concentrated on stress, mental fatigue, athletic performance (especially endurance), and mild-to-moderate depression. The research base is moderate in size - smaller than ashwagandha, larger than many other herbal supplements. Standardization to salidroside and rosavin content varies substantially across products, which complicates trial-to-trial comparison.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Adaptogenic herb traditionally used in Russian and Scandinavian folk medicine. Active compounds include salidroside...
Study coverage
Study coverage by goal
PubMed counts for Rhodiola grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Rhodiola.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Rhodiola rosea (golden root, arctic root) is one of the better-studied adaptogenic herbs, with a clinical literature spanning stress and burnout, mental fatigue, mild-to-moderate depression, athletic performance and recovery, and cognitive function under fatigue or sleep deprivation. The herb has been used in Russian and Scandinavian folk medicine for centuries; modern research uses standardized root extracts, most commonly the SHR-5 extract that dominates the European trial literature. Active compounds include salidroside (a tyrosol glucoside) and rosavins (phenylpropanoids); the salidroside-to-rosavin ratio is one of the standardization markers but is not consistent across products.
The outcome dimensions covered most heavily are stress and burnout symptoms (the primary established use in the European literature), mental fatigue and cognitive function under demanding conditions, athletic performance (particularly endurance, where the literature has focused on perceived exertion and time-to-exhaustion outcomes), mild-to-moderate depression (a smaller research stream), and adaptive resilience to acute physical or psychological stressors. The mechanistic emphasis on the HPA axis and monoaminergic systems connects rhodiola to the broader adaptogen category and shapes much of the field framing.
Demographically, the European literature concentrates heavily on healthy adults under occupational stress (the dominant trial population), with secondary research streams in athletic populations, students under examination stress, and clinical anxiety/depression. Product standardization is a major practical issue: trials variously use products standardized to 3% rosavins / 1% salidroside (the SHR-5 ratio), 6% rosavins, or pure salidroside, and these are not interchangeable. Trial duration is typically 4-12 weeks, similar to other herbal-supplement trials and shorter than ideal for establishing long-term effects.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Rhodiola is generally well-tolerated in clinical trials. The most-reported adverse events are mild gastrointestinal discomfort, dry mouth, dizziness, and occasional headache. Some users report increased irritability or restlessness, particularly at higher doses or with bedtime administration; morning administration is typical for this reason. No established tolerable upper limit. Drug interactions are not well-characterized in clinical trials; theoretical interactions with antidepressants (especially MAOIs and SSRIs given monoamine effects), stimulants, and antihypertensives have been raised but are not consistently documented in trial data. People with bipolar disorder, on antidepressants, or pregnant should consult a clinician.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Recent systematic review providing a comprehensive overview of Rhodiola rosea's adaptogenic effects with molecular interpretation of psychometric outcomes. While the document also covers ashwagandha, it provides the most-current supplement-overall framing for Rhodiola's adaptogenic claims.
View on PubMedRecent systematic review on Rhodiola's effects in sports performance, covering endurance, anaerobic exercise, and perceived exertion. The field reference for one of Rhodiola's most-asked consumer uses beyond stress and fatigue.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the Rhodiola literature at a general level. It does not address which extract (SHR-5 ratio, higher-rosavin formulations, or pure salidroside) is right for your specific goal, what dose has been shown effective for your use case, the appropriate timing of administration (morning typically, due to occasional stimulant-like effects), or how Rhodiola interacts with the medications you take (especially antidepressants). Product standardization variability is the single most-practical question for this supplement, which makes the personalized report especially useful here.
Personalized to you
Get a personalized Rhodiola report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Rhodiola materially updates. No account required.